HomeCompareETCO vs MRK

ETCO vs MRK: Dividend Comparison 2026

ETCO yields 94.02% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETCO wins by $2.98M in total portfolio value
10 years
ETCO
ETCO
● Live price
94.02%
Share price
$11.36
Annual div
$10.68
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.04M
Annual income
$983,491.82
Full ETCO calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ETCO vs MRK

📍 ETCO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETCOMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETCO + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETCO pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETCO
Annual income on $10K today (after 15% tax)
$7,991.63/yr
After 10yr DRIP, annual income (after tax)
$835,968.05/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ETCO beats the other by $827,639.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETCO + MRK for your $10,000?

ETCO: 50%MRK: 50%
100% MRK50/50100% ETCO
Portfolio after 10yr
$1.55M
Annual income
$496,644.98/yr
Blended yield
32.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ETCO
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETCO buys
0
MRK buys
0
No recent congressional trades found for ETCO or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETCOMRK
Forward yield94.02%2.76%
Annual dividend / share$10.68$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3.04M$56.8K
Annual income after 10y$983,491.82$9,798.13
Total dividends collected$2.70M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ETCO vs MRK ($10,000, DRIP)

YearETCO PortfolioETCO Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$20,102$9,401.92$11,206$366.19+$8.9KETCO
2$39,172$17,663.24$12,650$502.35+$26.5KETCO
3$74,083$32,168.28$14,407$694.19+$59.7KETCO
4$136,125$56,856.69$16,585$967.82+$119.5KETCO
5$243,292$97,638.17$19,342$1,363.89+$223.9KETCO
6$423,412$163,089.32$22,913$1,947.19+$400.5KETCO
7$718,314$265,263.07$27,662$2,823.89+$690.7KETCO
8$1,189,171$420,575.73$34,159$4,173.35+$1.16METCO
9$1,923,128$650,714.87$43,337$6,308.80+$1.88METCO
10$3,041,239$983,491.82$56,776$9,798.13+$2.98METCO

ETCO vs MRK: Complete Analysis 2026

ETCOStock

The Grayscale Ethereum Covered Call ETF (the “Fund”) seeks to provide current income. The Fund’s secondary objective is to participate in the returns of Ether through the use of options on Ethereum ETPs whose investment objectives are to, before fees and expenses, track the price performance of Ether. The Ethereum ETPs include, but are not limited to, Grayscale Ethereum Trust ETF (Ticker: ETHE) and Grayscale Ethereum Mini Trust ETF (Ticker: ETH) (the “Ethereum ETPs”).

Full ETCO Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ETCO vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETCO vs SCHDETCO vs JEPIETCO vs OETCO vs KOETCO vs MAINETCO vs JNJETCO vs ABBVETCO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.